[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360871-105":59,"doc-detail-360871-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hippo-pathway-at-the-crossroads-of-stemness-and-therapeutic-resistance-in-breast-cancer","Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer","","Breast cancer shows marked molecular heterogeneity, and breast cancer stem cells are implicated in tumor diversity, distant dissemination, and therapeutic resistance. The review focuses on how the Hippo signaling pathway interfaces with stemness programs and the mechanisms that blunt effective cancer therapy, with emphasis on pathways relevant to cancer progression. Special attention is given to resistance in the context of breast cancer subtypes, including triple-negative breast cancer, integrating key molecular players.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hippo-pathway-at-the-crossroads-of-stemness-and-therapeutic-resistance-in-breast-cancer/360871/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hippo-pathway-at-the-crossroads-of-stemness-and-therapeutic-resistance-in-breast-cancer/360871.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are breast cancer stem cells important in breast cancer?","Question",{"text":112,"@type":113},"Breast cancer stem cells contribute to tumor heterogeneity and distant dissemination, supporting disease progression and therapeutic failure.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of the Hippo pathway in this review?",{"text":117,"@type":113},"The review describes the Hippo pathway as a key regulator relevant to organogenesis and tissue development, linking it to stemness and cancer-related outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"How does this review connect Hippo signaling to therapeutic resistance?",{"text":121,"@type":113},"It discusses how pathways associated with stemness are intertwined with mechanisms that drive or sustain resistance to cancer therapies in breast cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360871,1790197784,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","REVIEW  \nHippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer  \nGiulia Schiavoni 1,2, Antonella Palmese3, Stefano Scalera 1, Laura Cipriani 1, Davide Mascolo 1,4, Patrizia Vici5, Teresa Arcuri5, Lorena Filomeno5, Eriseld Krasniqi5, Giovanni Blandino6, Giulia Bon3  and Marcello Maugeri-Sacc1,7  \n1 Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n2 Cellular and Molecular Biology, Department of Biology, University of Rome “Tor Vergata”, Italy  \n3 Cellular Network and Molecular Therapeutic Target Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n4 Department of Computer, Automatic and Management Engineering (DIAG), Sapienza University of Rome, Italy  \n5 Phase IV Studies, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n6 Oncogenomic and Epigenetic Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \n7 Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy  \nKeywords  \nbreast cancer; cancer therapy resistance; Hippo pathway; stemness; triple-negative breast cancer  \nBreast cancer, the most frequently diagnosed cancer in women globally, is a heterogeneous disease with distinct subtypes requiring distinct therapeutic approaches. Regardless of molecular subtyping, breast cancer stem cells significantly contribute to tumor heterogeneity, distant dissemination, and  \nAbbreviations  \nADC, antibody-drug conjugate; Akt, AKT serine/threonine kinase 1; ALDH1, aldehyde dehydrogenase 1; AMOTL1, Angiomotin like 1; Amotp80, Angiomotin p80; AMPK, AMP-activated protein kinase; ANKRD1, ankyrin repeat domain 1; BC, breast cancer; BCSCs, breast cancer stem cells; BRD4, bromodomain-containing protein 4; CCDC80, coiled-coil domain-containing 80; CCL2, chemokine (C-C motif) ligand 2; CCR2, C-C chemokine receptor 2; Cdk1, cyclin-dependent kinase 1; CDK4/6, cyclin-dependent kinase 4 and 6; CDK7, cyclin-dependent kinase 7; CDK9, cyclin-dependent kinase 9; CPZ, chlorpromazine; CSCs, cancer stem cells; CTGF, connective tissue growth factor; CYR61, Cysteine-rich angiogenic inducer 61; DDR, DNA damage response; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; ER, estrogen receptor; ERK, extracellular signal regulated kinase; F3, Coagulation factor III; FAT1, FAT atypical cadherin 1; FOXM1, forkhead box protein M1; GADD45A, growth arrest and DNA damage inducible alpha; GAP, GTPase-activating protein; GPCR, G-protein-coupled receptors; GPER, G-protein-coupled estrogen receptor; GRK3, G protein-coupled receptor kinase 3; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; HMG-CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A; HR, hormone receptor; IGF-1, insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; IL-6, interleukin 6; LATS1/2, large tumor suppressor 1 and 2; LEF, lymphoid enhancer factor; LIFR, leukemia inhibitory factor receptor; lncRNA, long non-coding RNA; MAPK, mitogen-activated protein kinase; MEKK3, mitogen-activated protein kinase kinase kinase 3; miRNA, microRNA; MOB1A/B, MOB kinase activator 1A and 1B; MST1/2, mammalian sterile 20-like kinase 1 and 2; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; MYH9, myosin heavy chain 9; NANOG, homebox protein NANOG; NCoR2, nuclear receptor corepressor 2; NF2, neurofibromin 2; OTUD5, OUT deubiquitinase 5; PD-L1, programmed death-ligand 1; PDX, patient-derived xenograft; PI3K, phosphoinositide 3-kinase; RAD18, RAD18 E3 ubiquitin protein ligase; RhoGAP, interacting with CIP4 homologs protein 1; RICH1, RhoA: Ras homolog family member A; ROCK,  \nRho-associated protein kinase; ROR1, type 1 receptor tyrosine kinase-like orphan receptor; RUNX1, Runt-related transcription factor 1; RUNX2, Runt-related transcription ","cbCaiqlFD6Pq12Rz","https://ap.wps.com/l/cbCaiqlFD6Pq12Rz","pdf",2005539,27,"English","# Review overview\n## Breast cancer heterogeneity and stemness\n## Hippo pathway as a regulator\n## Therapeutic resistance and tumor progression\n## Focus on triple-negative breast cancer","[{\"question\":\"Why are breast cancer stem cells important in breast cancer?\",\"answer\":\"Breast cancer stem cells contribute to tumor heterogeneity and distant dissemination, supporting disease progression and therapeutic failure.\"},{\"question\":\"What is the role of the Hippo pathway in this review?\",\"answer\":\"The review describes the Hippo pathway as a key regulator relevant to organogenesis and tissue development, linking it to stemness and cancer-related outcomes.\"},{\"question\":\"How does this review connect Hippo signaling to therapeutic resistance?\",\"answer\":\"It discusses how pathways associated with stemness are intertwined with mechanisms that drive or sustain resistance to cancer therapies in breast cancer.\"}]","Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer | PDF",1790141879,68]